journal article·2017-09-20

Hypotoxic and Rapidly Metabolic PEG-PCL-C3-ICG Nanoparticles for Fluorescence-Guided Photothermal/Photodynamic Therapy against OSCC

Shuangshuang Ren, Xiao Cheng, Mengkun Chen, Chao Liu, Peichen Zhao, Wei Huang, Jian He, Zhengyang Zhou, Leiying Miao

Publisher page

Abstract

The development of agents for noninvasive photothermal/photodynamic therapies (PTT/PDT) against cancer remains challenging because most PTT agents cause side effects on normal tissues due to their high cytotoxicity and slow metabolism rate. We successfully synthesized an organic compound (C3), encapsulated in PEG-PCL with indocyanine green (ICG), to form hybrid nanoparticles (PEG-PCL-C3-ICG NPs) for use as a new PPT/PDT agent to treat cancer with a single irradiation. Compared with conventional PPT agents, such as Au nanorods, C3 showed better photothermal conversion stability, lower cytotoxicity and a faster metabolic rate, ensuring promising PTT efficacy in eliminating tumors during in vivo application, while ICG was used as a PDT agent. With 808 nm laser irradiation at tumor sites, the PEG-PCL-C3-ICG NPs were able to simultaneously produce hyperthermia through C3 and produce reactive oxygen species as well as a fluorescence-guided effect through ICG to kill oral squamous cell carcinoma (OSCC) cells. The combination of these hypotoxic and metabolic hybrid nanoparticles with radiation therapy has potential for the future treatment of OSCC.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Extracellular vesicles in disease · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Radiology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing University, Nanjing, Jiangsu 210008, P. R. China

Funding

Natural Science Foundation of Jiangsu Province · National Natural Science Foundation of China · Nanjing Department of Health

References (34)

Show source-provided references
1. 10.1200/JCO.2015.61.292910.1200/JCO.2015.61.2929 ↗
2. 10.7314/APJCP.2013.14.10.556710.7314/APJCP.2013.14.10.5567 ↗
3. 10.1016/j.oraloncology.2008.06.00210.1016/j.oraloncology.2008.06.002 ↗
4. 10.1097/01.pas.0000149687.90710.2110.1097/01.pas.0000149687.90710.21 ↗
5. 10.21037/atm.2016.03.3410.21037/atm.2016.03.34 ↗
6. 10.1038/mt.2015.16910.1038/mt.2015.169 ↗
7. 10.1021/acsami.7b0301710.1021/acsami.7b03017 ↗
8. 10.1021/acsami.6b1670510.1021/acsami.6b16705 ↗
9. 10.1021/acsami.7b0136510.1021/acsami.7b01365 ↗
10. 10.1021/acsami.6b1157910.1021/acsami.6b11579 ↗
11. 10.1021/acsami.6b1349310.1021/acsami.6b13493 ↗
12. 10.1021/ar400195t10.1021/ar400195t ↗
13. 10.1002/adma.20130087510.1002/adma.201300875 ↗
14. 10.1002/anie.20141089510.1002/anie.201410895 ↗
15. 10.1021/nn202774x10.1021/nn202774x ↗
16. 10.1002/anie.20120235610.1002/anie.201202356 ↗
17. 10.1021/acsami.6b1676410.1021/acsami.6b16764 ↗
18. 10.1021/acsami.6b0555010.1021/acsami.6b05550 ↗
19. 10.1021/am500090510.1021/am5000905 ↗
20. 10.1021/acsami.6b1070210.1021/acsami.6b10702 ↗
21. 10.1021/acsami.6b0572710.1021/acsami.6b05727 ↗
22. 10.1021/acsami.6b1663410.1021/acsami.6b16634 ↗
23. 10.1039/c3nr05455a10.1039/c3nr05455a ↗
24. 10.1016/j.biomaterials.2015.08.00810.1016/j.biomaterials.2015.08.008 ↗
25. 10.1016/j.biomaterials.2015.04.00510.1016/j.biomaterials.2015.04.005 ↗
26. 10.1039/C1CS15188F10.1039/C1CS15188F ↗
27. 10.1021/bc025597h10.1021/bc025597h ↗
28. 10.1021/acsami.5b0102710.1021/acsami.5b01027 ↗
29. 10.1021/jo502899p10.1021/jo502899p ↗
30. 10.1016/j.biomaterials.2014.08.01310.1016/j.biomaterials.2014.08.013 ↗
31. 10.1039/C6RA28161C10.1039/C6RA28161C ↗
32. 10.1111/micc.1222810.1111/micc.12228 ↗
33. 10.1007/978-1-4939-3515-4_210.1007/978-1-4939-3515-4_2 ↗
34. 10.1016/j.addr.2015.01.00210.1016/j.addr.2015.01.002 ↗